FindTrial
Sign In

A Phase 2 Trial of ALIMTA (Pemetrexed) Plus Gemcitabine in Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00034593
Enrollment
Unknown
Registered
2002-05-01
Start date
Unknown
Completion date
Unknown
Last updated
2006-07-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urologic Neoplasms

Keywords

Bladder cancer, metastatic, transitional cell carcinoma of the urothelium

Brief summary

Definition: Patients with bladder cancer will be participating in this study for the treatment of abnormal cells in the bladder that have returned after initial treatment OR have moved to a new site in the body.

Interventions

DRUGALIMTA
DRUGgemcitabine

Sponsors

Eli Lilly and Company
Lead SponsorINDUSTRY

Study design

Primary purpose
TREATMENT

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* You must have been diagnosed with bladder cancer that has recurred or moved to a new part of the body. * You must have at least one tumor that can be physically measured or scanned by x-ray. * You may not have had previous chemotherapy (drug) treatment OR you have had surgery followed by one chemotherapy treatment at least 4 months ago.

Exclusion criteria

* You may not have used an experimental medicine or device within the past month. * Cancer that has spread to your brain. * If you are unwilling or unable to take folic acid or vitamin B12 supplements.

Countries

Finland, France, Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026